Skip to main content
. 2024 Jul 22;15(7):522. doi: 10.1038/s41419-024-06902-4

Fig. 2. Erianin promotes TMZ sensitivity in TMZ-resistant GSCs.

Fig. 2

a, b IC50 of U87, GSCm01, and our established TMZ-resistant U87R, GSCm01R at 24 h after with TMZ treatment, measured using CCK-8. c, d Cell viability measured using CCK-8 after 24, 48, and 72 h of treatment with TMZ, erianin, and their combination in U87R and GSCm01R. e, f Representative EdU assay showing proliferation and quantitative analysis of U87R and GSCm01R after different treatment groups. Scale bar = 50 μm. g, h Migration assays of U87 and U118 using a Transwell 24-well plate without extracellular matrix gel, and quantitative analysis after different treatment groups. Scale bar = 50 μm. i, j Invasion assays of U87 and U118 using a Transwell 24-well plate with extracellular matrix gel, and quantitative analysis after different treatment groups. Scale bar = 50 μm. k, m NSFA showing the size of neurospheres and quantitative analysis of GSCm01R after different treatment groups. Scale bar = 50 μm. l ELDA showing the neurosphere-forming ability of GSCm01R after different treatment groups. n Western blotting of stemness marker in GSCm01R after different treatment groups. All data are shown as the mean ± SD (five independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001; ns no significance.